Identification of Two New HLA-DQA1 Alleles: HLA-DQA1*01:173 and -DQA1*03:82.

HLA-DQA1*01:173 and -DQA1*03:82, two novel HLA-DQA1 alleles detected by next generation sequencing.

Ultrasmall solid lipid nanoparticles as a potential innovative delivery system for a drug combination against glioma.

Introduction: High grade gliomas are characterized by a very poor prognosis due to fatal relapses after surgery. Current chemotherapy is only a palliative care, while potential drug candidates are limited by poor overcoming of the blood-brain barrier.

Aims: A suitable chemotherapeutic approach should be engineered to overcome both the altered blood-brain barrier in the glioma site, as well as the intact one in the brain adjacent to tumor zone, and to target the multiple factors influencing glioma proliferation, differentiation, migration, and angiogenesis.

Early Monitoring of Donor-Derived Cell-Free DNA in Kidney Allograft Recipients Followed-Up for Two Years: Experience of One Center.

(1) Background: donor-derived circulating free DNA (dd-cfDNA), an innovative biomarker with great potential for the early identification and prevention of graft damage. (2) Methods: Samples were collected prospectively and the study was performed retrospectively to analyze dd-cfDNA plasma levels in 30 kidney transplant patients during their post-transplant follow-up (15 days, 3, 6, and 9 months), to determine if the result could be of interest in the identification of possible adverse events, especially rejection. The aim was to verify whether the data on sensitivity, specificity, NPV, and PPV compare with reference values and creatinine values.

Identification of three new HLA-A intronic variants by next-generation sequencing.

Three novel HLA-A intronic variants, HLA-A*03:01:01:121, HLA-A*29:02:01:41 and HLA-A*30:02:01:24, detected by next-generation sequencing.